Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 4.45B | 4.08B | 3.20B | 2.32B | 1.40B |
Gross Profit | 1.31B | 1.29B | 1.02B | 744.66M | 471.96M |
EBITDA | 999.10M | 1.11B | 868.43M | 623.67M | 385.36M |
Net Income | 598.26M | 682.93M | 476.78M | 441.46M | 170.09M |
Balance Sheet | |||||
Total Assets | 10.93B | 10.73B | 7.24B | 6.69B | 4.70B |
Cash, Cash Equivalents and Short-Term Investments | 651.59M | 768.00M | 884.71M | 1.10B | 2.58B |
Total Debt | 2.79B | 2.72B | 1.29B | 1.23B | 2.48M |
Total Liabilities | 4.25B | 4.48B | 2.30B | 2.21B | 359.93M |
Stockholders Equity | 6.65B | 6.23B | 4.93B | 4.46B | 4.27B |
Cash Flow | |||||
Free Cash Flow | 92.02M | -157.98M | 92.26M | -236.84M | -25.77M |
Operating Cash Flow | 707.13M | 782.84M | 685.38M | 426.25M | 296.13M |
Investing Cash Flow | -671.09M | -2.86B | -372.06M | -850.85M | -2.48B |
Financing Cash Flow | -216.56M | 1.78B | -154.21M | 754.50M | 2.17B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
76 Outperform | HK$6.81B | 26.84 | 26.24% | 1.63% | 17.69% | 5.37% | |
70 Outperform | HK$8.26B | 26.29 | 2.78% | 1.98% | -1.04% | -20.43% | |
68 Neutral | HK$9.41B | 14.86 | 9.30% | ― | 7.28% | -13.77% | |
67 Neutral | HK$8.10B | 25.02 | 13.13% | 2.39% | 28.02% | 19.41% | |
66 Neutral | HK$601.91M | 36.22 | 1.07% | 8.89% | -1.20% | -87.51% | |
66 Neutral | HK$1.70B | 5.28 | 24.13% | 4.21% | -3.85% | -19.28% | |
60 Neutral | HK$15.71B | 5.67 | -7.43% | 4.09% | 11.60% | -21.06% |
Hygeia Healthcare Holdings Co., Ltd. announced the results of its Annual General Meeting held on June 27, 2025, where all proposed resolutions were passed by shareholder vote. A significant change was the appointment of Deloitte Touche Tohmatsu as the new auditor, which may impact the company’s financial auditing processes and stakeholder confidence.
The most recent analyst rating on (HK:6078) stock is a Buy with a HK$37.00 price target. To see the full list of analyst forecasts on Hygeia Healthcare Holdings Co., Ltd. stock, see the HK:6078 Stock Forecast page.
Hygeia Healthcare Holdings Co., Ltd. has announced its upcoming Annual General Meeting scheduled for June 27, 2025, in Hong Kong. The meeting will address several key resolutions, including the adoption of financial statements, re-election of directors, appointment of auditors, and authorization for the board to manage share allotments. These resolutions are crucial for the company’s governance and strategic direction, potentially impacting its operational and financial management.
The most recent analyst rating on (HK:6078) stock is a Buy with a HK$37.00 price target. To see the full list of analyst forecasts on Hygeia Healthcare Holdings Co., Ltd. stock, see the HK:6078 Stock Forecast page.
Hygeia Healthcare Holdings Co., Ltd. has entered into a new 2025 Procurement Framework Agreement with Handan Renhe Hospital, replacing the existing procurement agreements. This agreement allows Gamma Star Tech, a subsidiary of Hygeia, to supply medicine and medical consumables to Handan Renhe Hospital, enhancing operational efficiency and continuing their business relationship. The transactions are classified as continuing connected transactions under Hong Kong’s Listing Rules, requiring reporting and annual review but exempt from independent shareholders’ approval due to the percentage ratios involved.
The most recent analyst rating on (HK:6078) stock is a Buy with a HK$37.00 price target. To see the full list of analyst forecasts on Hygeia Healthcare Holdings Co., Ltd. stock, see the HK:6078 Stock Forecast page.
Hygeia Healthcare Holdings Co., Ltd. has announced several changes in its board and operations, including the retirement of Mr. Liu Yanqun from his roles as an independent non-executive director and various committee positions, effective May 29, 2025. Mr. Zhang Guozhong, with over 25 years of experience in healthcare management, has been appointed as the new independent non-executive director. Additionally, the company is proposing a change of auditor and has updated its principal place of business in Hong Kong. These changes are expected to enhance the company’s governance and operational efficiency.
The most recent analyst rating on (HK:6078) stock is a Buy with a HK$37.00 price target. To see the full list of analyst forecasts on Hygeia Healthcare Holdings Co., Ltd. stock, see the HK:6078 Stock Forecast page.
Hygeia Healthcare Holdings Co., Ltd. has announced the composition of its board of directors and their respective roles within the company. This announcement details the executive and independent non-executive directors, as well as their participation in various board committees, which is crucial for stakeholders to understand the governance structure and leadership dynamics of the company.
The most recent analyst rating on (HK:6078) stock is a Buy with a HK$37.00 price target. To see the full list of analyst forecasts on Hygeia Healthcare Holdings Co., Ltd. stock, see the HK:6078 Stock Forecast page.